Open AccessImproving Disease-Free Survival in Resectable NSCLC
Author(s) -
Mark L. Fuerst
Publication year - 2021
Publication title -
oncology times
Language(s) - Uncategorized
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000798140.78947.bc
Subject(s) - medicine , clinical endpoint , oncology , atezolizumab , lung cancer , population , stage (stratigraphy) , clinical trial , cancer , surgery , paleontology , environmental health , immunotherapy , pembrolizumab , biology